# Honghui Capital

> Honghui Capital is a VC fund backing Health Care, Biotechnology and Manufacturing. See 16 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 16
- Last investment: Oct 2025
- Lead investor: 19%
- Last updated: Aug 2026
- Website: http://honghuicapital.com/

Honghui Capital is a private equity firm that provides primarily growth capital to companies in China.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 6 | 38% |
| Biotechnology | 5 | 31% |
| Manufacturing | 4 | 25% |
| Medical | 3 | 19% |
| Biopharma | 3 | 19% |

24 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 4 | 25% |
| Series B | 4 | 25% |
| Series C | 3 | 19% |
| Series A | 2 | 13% |
| Angel | 1 | 6% |

7 stages tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Realm of Illumination | Realm of Illumination is an AI smarter hardware developer that focuses on the research and development of AI smart terminal equipment and sensors to fulfill the application needs of artificial intelligence and the Internet of Things. | $27M | Seed | Oct 15, 2025 |  |
| VelaVigo | VelaVigo is a start-up company engaged in macromolecular biopharmaceuticals. | $50M | Seed | Dec 31, 2024 |  |
| Shanghai Peptide Biotechnology | Shanghai Peptide Biotechnology is a developer of nutritional food and beverage products for digestive and gastrointestinal ailments. | $140K | Seed | Sep 29, 2024 |  |
| Hanhua Semiconductor | Hanhua Semiconductor is a manufacturer of semiconductor components, integrating R&D, production, sales and service. |  | Series B | Sep 17, 2022 |  |
| Artivila Therapeutics | Artivila Therapeutics is a pharmaceutical company focused on improving patient's lives through an AI-powered drug discovery engine. The company is committed to discover the best therapeutical solutions to neuro-degenerative diseases, cancers, and autoimmune diseases empowered with an integrated AI-driven innovative drug discovery platform,providing first-in-class new molecules consistently and efficiently.Artivila Therapeutics was founded in 2018 and is based in ShenZhen, China. | $15.8M | Seed | Mar 31, 2022 |  |
| Tongxin Medical Equipment | Tongxin makes magnetically-suspended artificial blood pumps which are designed to replace the human heart. They are undergoing clinical trials in China after being fast-tracked through the approval process by the National Medical Products Administration, state-run Xinhua News Agency | $100M | Series D | Jan 25, 2022 |  |
| Bichen Pharmaceutical | Bichen Pharmaceutical is a small-molecule tumor-targeted drug developer for the treatment of various malignant tumors and brain metastases. | $30M | Series B | Jan 04, 2022 |  |
| ColorTech Bio | ColorTech Bio researches and develops precision molecular diagnostic equipment. It offers medical devices to improve biotechnology services and solutions. ColorTech Bio was founded in 2018 and is based in Suzhou, China. | $23.5M | Series B | Dec 20, 2021 |  |
| VelaVigo | VelaVigo is a start-up company engaged in macromolecular biopharmaceuticals. | $50M | Angel | Nov 15, 2021 |  |
| Eighteeth | Eighteeth focuses on the research and production of dental instruments. Eighteeth has 14 product categories including endo motor, apex locator, ultrasonic scaler, curing light, X-Ray unit, intraoral sensor, intraoral scanner, and owns 110 authorized patents. |  | Series A | Jul 19, 2021 |  |

10 of 16 investments shown.

## Co-investors
- [CDH Investments](https://shizune.co/investors/profile/cdh-investments) — VC Fund, 3 deals together
- [Highlight Capital](https://shizune.co/investors/profile/highlight-capital-llc) — VC Fund, 3 deals together
- [CS Capital](https://shizune.co/investors/profile/cs-capital) — VC Fund, 2 deals together
- [HSG](https://shizune.co/investors/profile/hsg-cap) — VC Fund, 2 deals together
- [Panacea Venture](https://shizune.co/investors/profile/panacea-venture-bb23) — VC Fund, 2 deals together
- [HSG](https://shizune.co/investors/profile/sequoia-capital-china) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Honghui Capital invest in?

Honghui Capital invests primarily in Health Care, Biotechnology and Manufacturing startups, most often at Seed and Series B stage. Most of the 16 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Honghui Capital last invest?

The most recent investment recorded for Honghui Capital closed in Oct 2025. Shizune tracks 16 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co